Source comparison
CJC-1295 no DAC vs With DAC — Why Dosing Frequency Changes
CJC-1295 exists in two forms: with DAC (Drug Affinity Complex) and without DAC. The DAC modification is a synthetic linker that binds to serum albumin, extending the peptide's half-life from 30 minutes to approximately 6–8 days. This extended half-life allows
This comparison does not assign a generated winner or score.
- CJC-1295 exists in two forms: with DAC (Drug Affinity Complex) and without DAC. The DAC modification is a synthetic linker that binds to serum albumin, extending the peptide's half-life from 30 minutes to approximately 6–8 days. This extended half-life allows once-weekly dosing but creates a sustained, non-pulsatile elevation of growth hormone. Which doesn't match the body's natural secretion pattern. Research published in the Journal of Clinical Endocrinology & Metabolism found that physiological GH release occurs in 6–10 discrete pulses per day, with peak amplitude during deep sleep and secondary pulses following exercise or fasting.
- CJC-1295 no DAC was developed specifically to preserve this pulsatile pattern. Without the albumin-binding DAC modification, the peptide clears rapidly. Plasma levels peak within 30 minutes of subcutaneous injection and return to baseline within 2–3 hours. This short duration forces multiple-times-daily dosing but allows researchers to time injections around natural GH pulse windows: morning (cortisol awakening response period) and pre-sleep (slow-wave sleep onset). Ipamorelin complements this timing because it's a selective ghrelin receptor agonist with minimal impact on cortisol or prolactin. Making it safe for repeat daily administration without hormonal disruption.
- Our team has found that researchers who attempt once-daily dosing with CJC-1295 no DAC consistently report suboptimal outcomes in growth hormone-related biomarkers. The peptide simply doesn't stay active long enough to sustain effect across a 24-hour period.